Related Experiment Video
Updated: Jul 18, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Clinical trials assessing the optimal management of brain metastases--the state of play
Abstract:
These three clinical trials offer the opportunity to answer the controversies and uncertainties that exist in managing patients with brain metastases: for patients with solitary brain metastasis there is the EORTC trial, for patients with NSCLC, where there is a certainty that the patient should receive radiotherapy, there is TACTIC, and where there is uncertainty of the benefit of radiotherapy there is QUARTZ. We would encourage all clinical oncologists seeing patients with brain metastases to consider patients for entry into any one of these trials.
Insights
Three clinical trials address brain metastases management uncertainties. EORTC, TACTIC, and QUARTZ trials offer opportunities to resolve controversies in treating solitary brain metastasis, non-small cell lung cancer (NSCLC) patients, and radiotherapy benefit uncertainty.
Area of Science:
- Neuro-oncology
- Clinical Oncology
- Radiotherapy Research
Background:
- Managing brain metastases presents clinical controversies and uncertainties.
- Existing clinical trials aim to resolve these issues in specific patient populations.
- These include solitary brain metastasis, non-small cell lung cancer (NSCLC) with radiotherapy certainty, and cases with radiotherapy benefit uncertainty.
Discussion:
- The EORTC trial focuses on solitary brain metastasis.
- The TACTIC trial addresses NSCLC patients where radiotherapy is indicated.
- The QUARTZ trial investigates cases where radiotherapy benefit is uncertain.
Key Insights:
- These trials provide crucial data for evidence-based management of brain metastases.
- They aim to clarify treatment protocols and improve patient outcomes.
- Clinical oncologists are encouraged to enroll eligible patients.
Outlook:
- Further research through these trials will refine treatment strategies for brain metastases.
- Resolving current uncertainties will lead to more standardized and effective patient care.
- Potential for improved survival rates and quality of life in affected patients.
